Veru's VERU-111 Moves Into Pivotal COVID-19 Study

Veru Inc (NASDAQ: VERU) will start testing VERU-111 in the registrational Phase 3 study in hospitalized patients who have COVID-19 virus infection and are at high risk for Acute Respiratory Distress Syndrome. Mitchell Steiner, chairman, president, and CEO, said, "we have the resources to conduct a Phase 3 trial without...